Active — Not RecruitingNot Applicable

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

United States150 participantsStarted 2023-08-31

Plain-language summary

Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participant must be at least 18 years old.
✓. Participant must have a prior diagnosis of PCD or be deemed eligible upon completion of the PCD-enrichment screening questionnaire.
✓. Participant must be under the care of an HCP for their PCD or symptoms potentially related to PCD.
✓. Participant must be able to read, write, and understand English, and reside in a country where the shipment of biological samples is allowed.
✓. Participant must be willing to be tested for genes involved in PCD.
✓. Participant must be willing to be notified of eligibility for clinical studies (if appropriate)

What they're measuring

Number of PCD individuals with DNAI1 mutation identified through genetic testing

Timeframe: 2 years

Trial details

NCT IDNCT06172374

SponsorReCode Therapeutics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-04-30

View on ClinicalTrials.gov More Primary Ciliary Dyskinesia trials